Argenica Therapeutics Ltd · ASX:AGN
Argenica Therapeutics — ASX Small Caps Conference 2025
19 slides from Argenica Therapeutics's conference presentation, September 2025
Slide 1: Argenica Therapeutics Investor Presentation
ARGENICA THERAPEUTICS INVESTOR PRESENTATION ASX: AGN ASX SMALL CAPS CONFERENCE SEPTEMBER 2025 MANAGING DIRECTOR PRESENTATION 1 www.argenica.com.au
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Argenica Therapeutics Limited and its related entities (the “Company”) and is not an offer document. It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company
Slide 3: The Therapeutic Opportunity
NEUROPROTECTION ARGENICA THERAPEUTICS THE THERAPEUTIC OPPORTUNITY 3 www.argenica.com.au
Slide 4: Breakthrough Neuroprotective Therapy
BREAKTHROUGH NEUROPROTECTIVE THERAPY ABOUT ARG-007 MISSION Commercialise neuroprotective treatments that minimises brain damage and optimised recovery Proven safety in clinical trials following stroke & other neurological conditions ARGENICA THERAPEUTICS Clinically advanced following Phase 2 trial V
Slide 5: Our Lead Indications
OUR LEAD INDICATIONS DISCOVERY PRE-CLINICAL PHASE 1 PHASE 2 PHASE 2b Efficacy Safety / Tox Safety Safety/Efficacy STROKE – ARG-007 Damage to the brain from interruption of its blood supply MOD-SEVERE TBI – ARG-007 ARGENICA THERAPEUTICS Trauma to the head or body causes a loss of consciousness HIE –
Slide 6: Key Company Metrics
KEY COMPANY METRICS $10.5M $39M +$5M CASH @ BANK 1 MARKET CAP2 NON-DILUTIVE GRANTS 3 ARGENICA THERAPEUTICS 128.1M 37% SHARES HELD BY TOP 20 DATA SHARES ON ISSUE IN PHASE 2 STROKE TRIAL 1. Cash balance as @ 30 June 2025 6 2. Calculated with closing price on @19th September 2025 being $0.31 www.argeni
Slide 7: Ischaemic Stroke Opportunity
ISCHAEMIC STROKE ARGENICA THERAPEUTICS OPPORTUNITY 7 www.argenica.com.au
Slide 8: So Why Are We Targeting Stroke First?
SO WHY ARE WE TARGETING STROKE FIRST? INCIDENCE SOCIETAL IMPLICATIONS THE IMPORTANCE OF TIME ARGENICA THERAPEUTICS 45 SECONDS ONLY 10% 1.9 MILLION How often someone will recover almost brain cells die every minute suffers an ischaemic completely, due to the extent during a stroke3 stroke in the US1
Slide 9: Compelling Preclinical/Clinical Data
COMPELLING PRECLINICAL/CLINICAL DATA SUCCESSFUL PHASE 28 Days 1 (HUMAN after stroke in STUDY) PRECLINICAL & CLINICAL DATA preclinical model4 100% INDUCED Reduction in brain 90% STROKE cell death can make a significant difference SAFE TO 80% to patients’ outcome. ADMINISTER It could mean the IN THE F
Slide 10: Phase 2 Trial Design in Acute Ischaemic Stroke
PHASE 2 TRIAL DESIGN IN ACUTE ISCHAEMIC STROKE PATIENT HAS A PATIENT IN ARRIVES AT DIAGNOSE REHAB STROKE AMBULANCE HOSPITAL STROKE TYPE THROMBECTOMY BEGINS ARGENICA THERAPEUTICS Initial screening of Administration of PATIENT OUTCOME MEASURES patients to meet inclusion 0.3mg/kg ARG-007 or Safety i.e.
Slide 11: Phase 2 Clinical Trial in Stroke
PHASE 2 CLINICAL TRIAL IN STROKE 92 patients dosed at 8 Australian RAPID PATIENT RECRUITMENT hospitals 100 KEY OBJECTIVES: 90 ARGENICA THERAPEUTICS 80 1. Safety/Tolerability – significantly 70 derisks the drug, critical in Patients Dosed 60 neurology drug development 50 40 2. Pharmacokinetics – is t
Slide 12: Overview of Phase 2 Trial Results
OVERVIEW OF PHASE 2 TRIAL RESULTS Argenica’s Phase 2 trial for ARG-007 in AIS has met its primary endpoint and showed encouraging signal of efficacy in the “slow collateral” patients. Temporal profile of Treatment-Emergent Adverse Events KEY SUMMARY • Phase 2 double blinded, placebo-controlled trial
Slide 13: Are All Ischaemic Stroke Patients the Same?
ARE ALL ISCHAEMIC STROKE PATIENTS THE SAME?1 Patients with Good Collateral Blood flow already have good outcomes • Robust collateral blood flow maintains penumbra until EVT • High reperfusion success better functional outcomes • Neuroprotection targeting acute injury may not show benefit (tissue alr
Slide 14: Slow Collateral Patients – 30% of Participants
SLOW COLLATERAL PATIENTS – 30% OF PARTICIPANTS1 THE MOST AT-RISK PATIENTS OF VULNERABLE BRAIN TISSUE (PENUMBRA) TURNING TO INFARCT • Patients with slow/poor collaterals have highly vulnerable brain tissue that is not yet dead • This vulnerable tissue is where injury cascades are most active, ARGENIC
Slide 15: How Much Brain Do You Need to Save?
HOW MUCH BRAIN DO YOU NEED TO SAVE? CLINICALLY MEANINGFUL FINAL INFARCT VOLUME REDUCTIONS • A 0.6 mL, which equates to a 1.6% decrease in infarct 100% 1.6% volume (decrease in brain cell death), is the minimum INFARCT VOLUME REDUCTION (%) 90% Reduction amount of decrease deemed to be clinically impo
Slide 16: The Opportunity in Stroke
THE OPPORTUNITY IN STROKE Category Australia United States Number of strokes per year ~45,000 annually1 ~795,000 annually2 Cost of stroke to healthcare USD$71.55 billion in 2012 AUD$5.5 billion expected to increase to system per year in healthcare costs in 20231 USD$184.13 billion by 20303 ARGENICA
Slide 17: Post Phase 2 Strategy
POST PHASE 2 STRATEGY POST HOC ANALYSIS OF PHASE 2 DATA Identify the subgroups of AIS patients most likely to benefit from ARG- 007. This allows Argenica to design a Phase 2b trial with higher probability of success by focusing on the right patients and ensuring analysis of the right endpoints. ARGE
Slide 18: Encouraging Clinical Data
3# ENCOURAGING CLINICAL DATA Phase 2 acute ischaemic stroke trial results showed efficacy signal in most at risk patients with slow collaterals. Now have extensive patient data to design more targeted trial ARGENICA THERAPEUTICS 1# SOLVING LARGE UNMET NEEDS 2# Nervous system disorders are the SIGNIF
Slide 19: Argenica Therapeutics
ARGENICA THERAPEUTICS For further information please contact: Dr Liz Dallimore CEO & Managing Director E: info@argenica.com.au 19 www.argenica.com.au
Argenica Therapeutics — ASX Small Caps Conference 2025 on 6ix